Published in Br J Cancer on February 28, 2013
A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol (2013) 1.04
Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol (2014) 1.01
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol (2016) 0.97
ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr (2014) 0.80
Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma. World J Hepatol (2015) 0.79
Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford) (2015) 0.78
Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep (2014) 0.76
Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. United European Gastroenterol J (2016) 0.76
Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. J Vasc Interv Radiol (2015) 0.75
Clostridium perfringens infection after transarterial chemoembolization for large hepatocellular carcinoma. World J Gastroenterol (2015) 0.75
Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. Biomed Res Int (2015) 0.75
Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma (2016) 0.75
Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer (2017) 0.75
Value of quality of life analysis in liver cancer: A clinician's perspective. World J Hepatol (2017) 0.75
Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. Clin Transl Gastroenterol (2017) 0.75
ShRNA knock-down of CXCR7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization. J Cell Mol Med (2017) 0.75
The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. Liver Cancer (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (2009) 34.99
CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 22.34
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (1998) 6.47
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (2011) 3.73
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol (2006) 3.65
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol (2011) 3.03
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol (2012) 2.53
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol (2011) 2.37
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol (2011) 2.03
Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol (2011) 1.84
Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol (2009) 1.67
Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol (2004) 1.35
Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer (1994) 1.20
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist (2010) 1.16
Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol (1992) 1.15
Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol (1991) 0.94
Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol (2010) 0.92
The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011. J Vasc Interv Radiol (2011) 0.89
Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma. Ther Drug Monit (1996) 0.77
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics (2001) 15.03
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Screening and brief intervention for high-risk college student drinkers: results from a 2-year follow-up assessment. J Consult Clin Psychol (1998) 7.81
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell (1999) 5.63
Carcinoid tumour. Lancet (1998) 4.52
Replicating SV40 molecules containing closed circular template DNA strands. Nat New Biol (1971) 4.36
High efficiency mutagenesis, repair, and engineering of chromosomal DNA using single-stranded oligonucleotides. Proc Natl Acad Sci U S A (2001) 4.30
Trans-complex formation by proteolipid channels in the terminal phase of membrane fusion. Nature (2001) 4.10
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
High-resolution EEG mapping of cortical activation related to working memory: effects of task difficulty, type of processing, and practice. Cereb Cortex (1997) 4.00
Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther (2014) 3.98
Randomized clinical trial of routine on-table cholangiography during laparoscopic cholecystectomy. Br J Surg (2010) 3.63
Ca2+/calmodulin signals the completion of docking and triggers a late step of vacuole fusion. Nature (1998) 3.33
Cerebral response to patient's own name in the vegetative and minimally conscious states. Neurology (2007) 3.26
Rapid engineering of bacterial artificial chromosomes using oligonucleotides. Genesis (2001) 3.07
Secondary prevention with college drinkers: evaluation of an alcohol skills training program. J Consult Clin Psychol (1990) 3.05
Alpha-CaMKII-dependent plasticity in the cortex is required for permanent memory. Nature (2001) 3.04
Mutations in twinstar, a Drosophila gene encoding a cofilin/ADF homologue, result in defects in centrosome migration and cytokinesis. J Cell Biol (1995) 2.98
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation (2007) 2.93
A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis (1999) 2.93
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation (2009) 2.85
Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev (2007) 2.75
Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci U S A (1998) 2.71
Effect of introducing the Modified Early Warning score on clinical outcomes, cardio-pulmonary arrests and intensive care utilisation in acute medical admissions. Anaesthesia (2003) 2.54
Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. Biochem J (2001) 2.51
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol (2010) 2.50
Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J (1995) 2.39
Bacterial infection in the pathogenesis of variceal bleeding. Lancet (1999) 2.35
APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron (2001) 2.31
The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant (2012) 2.29
Mutable R-navajo alleles of cyclic origin in maize. Genetics (1973) 2.25
Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation (2001) 2.22
An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy (2006) 2.22
Coagulation and fibrosis in chronic liver disease. Gut (2008) 2.22
Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med (1999) 2.21
Herpes simplex virus DNA cleavage and packaging proteins associate with the procapsid prior to its maturation. J Virol (2001) 2.21
An experimental test of three methods of alcohol risk reduction with young adults. J Consult Clin Psychol (1992) 2.20
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem (1997) 2.14
Allosteric effects of Mg2+ on the gating of Ca2+-activated K+ channels from mammalian skeletal muscle. J Exp Biol (1986) 2.14
Systematic review and meta-analysis of intraoperative versus preoperative endoscopic sphincterotomy in patients with gallbladder and suspected common bile duct stones. Br J Surg (2011) 2.13
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
A molecular approach to leukemogenesis: mouse lymphomas contain an activated c-ras oncogene. Proc Natl Acad Sci U S A (1984) 2.07
Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol (1994) 2.05
Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut (2001) 2.02
Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther (2006) 2.00
Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol (2001) 2.00
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet (1999) 1.98
Access by general practitioners to physiotherapy department of a district general hospital. Br Med J (1975) 1.96
"Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology (1998) 1.95
Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut (2005) 1.93
Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol (2002) 1.92
Abdominal tuberculosis: the great mimic. Hosp Med (2001) 1.92
A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology (2002) 1.90
Differentiation of Bacillus anthracis and other 'Bacillus cereus group' bacteria using IS231-derived sequences. FEMS Microbiol Lett (1995) 1.88
An appraisal of the histopathological assessment of liver fibrosis. Gut (2006) 1.87
Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther (2005) 1.86
Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene (2009) 1.85
Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology (Oxford) (2006) 1.84
Factors associated with participation, attrition, and outcome in a smoking cessation program at the workplace. Health Psychol (1988) 1.83
Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol (1997) 1.82
NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland. Heart (2007) 1.80
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol (1999) 1.76
Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Lancet (2000) 1.75
Control of the terminal step of intracellular membrane fusion by protein phosphatase 1. Science (1999) 1.75
Prospective randomized double-blind trial between laparoscopic Nissen fundoplication and anterior partial fundoplication. Br J Surg (1999) 1.75
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene (2010) 1.70
Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab (2002) 1.70
Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut (1998) 1.63
Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev (2006) 1.63
Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo. J Virol (1997) 1.63
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost (2010) 1.62
AIDS treatment advances and behavioral prevention setbacks: preliminary assessment of reduced perceived threat of HIV-AIDS. Health Psychol (1998) 1.61
Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut (2006) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol (1999) 1.60
Biochemical markers of acute pancreatitis. J Clin Pathol (2006) 1.60
A heterodimer of thioredoxin and I(B)2 cooperates with Sec18p (NSF) to promote yeast vacuole inheritance. J Cell Biol (1997) 1.60
The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. Mamm Genome (1997) 1.59
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol (2013) 1.59
Review article: portal vein thrombosis -- new insights into aetiology and management. Aliment Pharmacol Ther (2005) 1.59
Active site mutants implicate key residues for control of color and light cycle kinetics of photoactive yellow protein. Biochemistry (1997) 1.59
The four community dimensions of primary care practice. J Fam Pract (1998) 1.59